ClinicalTrials.gov
skipnavHome|Search|Browse|Resources|Help|What's New|About

Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules - 1

This study is currently recruiting patients.

Sponsored by: National Institute on Drug Abuse (NIDA)
University of California, Los Angeles
Information provided by: National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this protocol is to to compare the clinical utility of two dosage tapering regimens in Buprenorphine/Naloxone stabilized subjects for opiate detoxification.

Condition Treatment or Intervention Phase
Opioid-Related Disorders
  Drug: Buprenorphine
 Phase III

MedlinePlus related topics:  Drug Abuse

Study Type: Interventional
Study Design: Treatment, Uncontrolled

Official Title: Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules

Further Study Details: 

Expected Total Enrollment:  484

Study start: January 2001

Eligibility

Ages Eligible for Study:  15 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:


Location and Contact Information

Jerry Cunningham-Rathner      (310)312-0500    jrathner@mednet.ucla.edu

Colorado
      Addiction Research & Treatment Services (ARTS), Denver,  Colorado,  80204,  United States; Recruiting
Jerry Cunningham-Rathner  310-312-0500    jrathner@mednet.ucla.edu 

      Denver Health & Hospitals Authority, Denver,  Colorado,  80204,  United States; Recruiting
Jerry Cunningham-Rathner  310-312-0500    jrathner@mednet.ucla.edu 

Connecticut
      Connecticut Counseling Centers, Waterbury,  Connecticut,  06705,  United States; Recruiting
Jerry Cunningham-Rathner  310-312-0500    jrathner@mednet.ucla.edu 

      Hartford Dispensary, Hartford,  Connecticut,  06120,  United States; Recruiting
Jerry Cunningham-Rathner  310-312-0500    jrathner@mednet.ucla.edu 

New York
      New York VA Medical Center, New York,  New York,  10010,  United States; Recruiting
Jerry Cunningham-Rathner  310-312-0500    jrathner@mednet.ucla.edu 

      LI Jewish Health System, Glen Oaks,  New York,  11004,  United States; Recruiting
Jerry Cunningham-Rathner  310-312-0500    jrathner@mednet.ucla.edu 

North Carolina
      Coastal Horizons Center, Inc., Wilmington,  North Carolina,  28412,  United States; Recruiting
Jerry Cunningham-Rathner  310-312-0500    jrathner@mednet.ucla.edu 

      South Light-Wakeview Clinic, Raleigh,  North Carolina,  27610,  United States; Recruiting
Jerry Cunningham-Rathner  310-312-0500    jrathner@mednet.ucla.edu 

Oregon
      CODA, Portland,  Oregon,  97214,  United States; Recruiting
Jerry Cunningham-Rathner  310-312-0500    jrathner@mednet.ucla.edu 

Virginia
      Norfolk CSB, Norfolk,  Virginia,  23505,  United States; Recruiting
Jerry Cunningham-Rathner  310-312-0500    jrathner@mednet.ucla.edu 

Washington
      Providence Behavioral Health Services, Everett,  Washington,  98201,  United States; Recruiting
Jerry Cunningham-Rathner  310-312-0500    jrathner@mednet.ucla.edu 

Study chairs or principal investigators

Jerry Cunningham-Rathner,  Principal Investigator,  University of California, Los Angeles   

More Information

Study ID Numbers:  NIDA-CTN-0003-1
Record last reviewed:  November 2004
Record first received:  February 19, 2004
ClinicalTrials.gov Identifier:  NCT00078117
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2004-11-08
line
U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act